Business Context and Reporting Period
West Pharmaceutical Services, Inc. designs and manufactures containment, packaging, drug-delivery and contract-manufactured products for biologic, generic, pharmaceutical, diagnostic and medical-device customers. The company reports two segments: Proprietary Products and Contract-Manufactured Products.
This unaudited Form 10-Q covers the three and six months ended June 30, 2020, compared with the corresponding 2019 periods. Results are presented in millions except per-share data.
Key Financial Metrics
| Metric | Q2 2020 | Q2 2019 | Six Months 2020 | Six Months 2019 |
|---|---|---|---|---|
| Net sales | $527.2 | $469.7 | $1,018.7 | $913.2 |
| Gross profit | $195.1 | $157.9 | $362.1 | $304.7 |
| Gross margin | 37.0% | 33.6% | 35.5% | 33.4% |
| Operating profit | $103.6 | $80.5 | $191.6 | $151.2 |
| Operating margin | 19.7% | 17.1% | 18.8% | 16.6% |
| Net income | $91.2 | $66.1 | $165.5 | $121.5 |
| Diluted EPS | $1.21 | $0.88 | $2.19 | $1.61 |
| Operating cash flow | Not separately provided | Not separately provided | $205.2 | $152.7 |
Q2 net sales increased 12.2% as reported and 14.3% excluding foreign-currency translation. Six-month sales increased 11.6% as reported and 13.5% excluding currency effects and the 2019 acquisition. Proprietary Products represented $399.5 million of Q2 sales, while Contract-Manufactured Products represented $127.8 million.
Q2 adjusted operating profit, excluding unallocated items, was $106.0 million, or 20.1% of sales, compared with $81.9 million, or 17.4%, in the prior-year quarter. Six-month adjusted operating profit was $194.0 million, or 19.0% of sales, compared with $153.2 million, or 16.8%.
Liquidity, Cash Flow and Capital Structure
- Cash and cash equivalents were $445.9 million at June 30, 2020, compared with $439.1 million at December 31, 2019.
- Working capital was $735.4 million, compared with $717.1 million at year-end 2019.
- Total debt was $256.2 million, compared with $257.3 million at December 31, 2019; long-term debt, net, was $253.9 million.
- The $300.0 million revolving credit facility had no borrowings outstanding and $297.5 million of available capacity, including $2.5 million of letters of credit.
- Six-month capital expenditures were $69.2 million, compared with $57.1 million in 2019. Investing cash outflows were $72.8 million.
- Financing cash outflows were $121.2 million, including $115.5 million for repurchases of 761,500 shares and $23.6 million of dividends.
- Management stated that cash on hand, operating cash flow and available credit are adequate for foreseeable liquidity needs. The company was in compliance with its debt covenants.
Material Changes Versus the Prior Comparable Period
- Proprietary Products sales increased 10.9% as reported and 13.3% organically in Q2; six-month organic growth was 12.6%. Growth reflected high-value components, delivery platforms and approximately $19 million of COVID-19-related activity for antiviral treatments and treatment of underlying COVID-19 symptoms.
- Contract-Manufactured Products sales increased 16.8% as reported and 17.8% organically in Q2, driven by healthcare-related injection and diagnostic devices.
- Gross margin expanded 3.4 percentage points in Q2 and 2.1 percentage points for the six-month period, primarily from favorable product mix, pricing and production efficiencies.
- Operating profit increased 28.7% in Q2 and 26.7% for the six-month period. Corporate costs increased, primarily because of higher stock-based compensation.
- The effective tax rate declined to 15.6% in Q2 from 19.4% and to 16.4% for six months from 21.1%, primarily because of increased tax benefits from stock-based compensation.
- Foreign-currency translation reduced Q2 sales by $9.6 million and six-month sales by $19.4 million.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide a specific numerical revenue or earnings outlook. Management reported that manufacturing facilities continued operating with minimal disruption and enhanced safety measures during the COVID-19 pandemic. However, the company could not predict the pandemic’s future effects.
- COVID-19 risks include employee illness, supplier or transportation interruptions, changing customer demand and government restrictions. Demand could increase or decrease unpredictably.
- Q2 included $6.3 million of fixed-asset impairments, compared with $1.2 million in the prior-year quarter. Six-month impairments were $6.5 million versus $1.6 million.
- The company recorded $2.2 million of severance-related costs and $0.2 million of acquisition-related intangible amortization as unallocated items in Q2 2020. Prior-year unallocated costs were restructuring charges of $1.4 million in Q2 and $2.0 million for six months.
- A pension settlement charge of $0.9 million in Q2 and $2.3 million for six months resulted from lump-sum payments exceeding the applicable settlement threshold.
- The 2019 Vial2Bag voluntary recall remained a relevant historical item, although 2020 results did not include the comparable 2019 return provisions. The company continued working to return the product to market.
- Key ongoing risks include demand and product mix, competition, supply-chain disruptions, regulatory approval and commercialization of customer products, dependence on critical suppliers and affiliates, raw-material costs, foreign exchange and healthcare legislation.
- The company reported no material changes to previously disclosed commitments and contingencies, no legal proceedings requiring disclosure, and no material off-balance-sheet financing arrangements.
Important Facts for Investors to Verify
- Whether COVID-19-related demand, including the approximately $19 million cited for the first half, persists or reverses.
- Whether expanded gross margins and production efficiencies are sustainable after product mix and pricing effects normalize.
- The nature, recoverability and potential recurrence of the $6.5 million year-to-date fixed-asset impairments.
- The company’s progress in resolving the Vial2Bag recall and any remaining product-liability or customer-return exposure.
- Foreign-exchange sensitivity, particularly given the $19.4 million first-half translation headwind and the company’s extensive hedging activity.
- Future capital allocation, including additional share repurchases, dividends, capital expenditures and debt repayment.
- The duration and operational effects of COVID-19, including supplier capacity, transportation access, employee health and customer ordering patterns.